PubMed=29755650; DOI=10.18632/oncotarget.24750; PMCID=PMC5945540
McHugh A., Fernandes K., South A.P., Mellerio J.E., Salas-Alanis J.C., Proby C.M., Leigh I.M., Saville M.K.
Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity.
Oncotarget 9:20265-20281(2018)

PubMed=30202019; DOI=10.1038/s41467-018-06027-1; PMCID=PMC6131170
Inman G.J., Wang J., Nagano A., Alexandrov L.B., Purdie K.J., Taylor R.G., Sherwood V., Thomson J., Hogan S., Spender L.C., South A.P., Stratton M.R., Chelala C., Harwood C.A., Proby C.M., Leigh I.M.
The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature.
Nat. Commun. 9:3667.1-3667.14(2018)

PubMed=31336867; DOI=10.3390/ijms20143428; PMCID=PMC6678499
Hassan S., Purdie K.J., Wang J., Harwood C.A., Proby C.M., Pourreyron C., Mladkova N., Nagano A., Dhayade S., Athineos D., Caley M., Mannella V., Blyth K., Inman G.J., Leigh I.M.
A Unique panel of patient-derived cutaneous squamous cell carcinoma cell lines provides a preclinical pathway for therapeutic testing.
Int. J. Mol. Sci. 20:3428.1-3428.26(2019)